2021 Q1 Form 10-Q Financial Statement
#000156459021024084 Filed on May 05, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $9.461M | $1.750M |
| YoY Change | 440.63% | 0.0% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $15.82M | $7.010M |
| YoY Change | 125.68% | 41.05% |
| % of Gross Profit | ||
| Research & Development | $66.39M | $23.14M |
| YoY Change | 186.87% | 48.78% |
| % of Gross Profit | ||
| Depreciation & Amortization | $800.0K | $800.0K |
| YoY Change | 0.0% | -20.0% |
| % of Gross Profit | ||
| Operating Expenses | $82.21M | $30.15M |
| YoY Change | 172.66% | 46.91% |
| Operating Profit | -$72.75M | -$28.40M |
| YoY Change | 156.15% | 51.28% |
| Interest Expense | $150.0K | $650.0K |
| YoY Change | -76.92% | -40.91% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $154.0K | |
| YoY Change | ||
| Pretax Income | -$72.59M | -$27.75M |
| YoY Change | 161.6% | 57.05% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$72.59M | -$27.75M |
| YoY Change | 161.57% | 57.06% |
| Net Earnings / Revenue | -767.29% | -1585.89% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$1.082M | -$626.7K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 70.88M | 44.28M |
| Diluted Shares Outstanding | 44.28M |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $826.9M | $157.9M |
| YoY Change | 423.69% | -34.73% |
| Cash & Equivalents | $390.3M | $67.33M |
| Short-Term Investments | $436.7M | $90.50M |
| Other Short-Term Assets | $8.700M | $8.000M |
| YoY Change | 8.75% | 158.06% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $6.300M | $300.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $841.9M | $166.2M |
| YoY Change | 406.51% | -32.16% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $27.10M | $8.761M |
| YoY Change | 209.33% | -20.35% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $58.00M | |
| YoY Change | ||
| Other Assets | $8.200M | $963.0K |
| YoY Change | 751.51% | 92.6% |
| Total Long-Term Assets | $93.20M | $9.927M |
| YoY Change | 838.85% | -26.38% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $841.9M | $166.2M |
| Total Long-Term Assets | $93.20M | $9.927M |
| Total Assets | $935.1M | $176.1M |
| YoY Change | 430.87% | -31.86% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $24.50M | $2.426M |
| YoY Change | 909.89% | -13.36% |
| Accrued Expenses | $7.536M | $10.17M |
| YoY Change | -25.9% | 33.82% |
| Deferred Revenue | $74.57M | $7.000M |
| YoY Change | 965.3% | 0.0% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $132.1M | $21.00M |
| YoY Change | 528.93% | 10.55% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $138.3M | $640.0K |
| YoY Change | 21509.38% | -96.44% |
| Total Long-Term Liabilities | $138.3M | $640.0K |
| YoY Change | 21509.38% | -96.44% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $132.1M | $21.00M |
| Total Long-Term Liabilities | $138.3M | $640.0K |
| Total Liabilities | $270.3M | $35.51M |
| YoY Change | 661.28% | -4.04% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$400.8M | -$233.1M |
| YoY Change | 71.95% | 68.55% |
| Common Stock | $7.000K | $4.000K |
| YoY Change | 75.0% | 0.0% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $664.8M | $140.6M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $935.1M | $176.1M |
| YoY Change | 430.88% | -31.87% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$72.59M | -$27.75M |
| YoY Change | 161.57% | 57.06% |
| Depreciation, Depletion And Amortization | $800.0K | $800.0K |
| YoY Change | 0.0% | -20.0% |
| Cash From Operating Activities | -$66.32M | -$31.28M |
| YoY Change | 112.03% | 85.74% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $3.641M | $209.0K |
| YoY Change | 1642.11% | -66.72% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $66.50M | $40.30M |
| YoY Change | 65.01% | 170.47% |
| Cash From Investing Activities | $62.83M | $40.06M |
| YoY Change | 56.85% | 180.52% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $220.2M | $643.0K |
| YoY Change | 34151.17% | |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 222.1M | 610.0K |
| YoY Change | 36313.11% | -12300.0% |
| NET CHANGE | ||
| Cash From Operating Activities | -66.32M | -31.28M |
| Cash From Investing Activities | 62.83M | 40.06M |
| Cash From Financing Activities | 222.1M | 610.0K |
| Net Change In Cash | 218.6M | 9.389M |
| YoY Change | 2228.58% | -466.04% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$66.32M | -$31.28M |
| Capital Expenditures | $3.641M | $209.0K |
| Free Cash Flow | -$69.96M | -$31.49M |
| YoY Change | 122.18% | 80.26% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
rcus:CollaborationMember | |
| CY2020Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
rcus:CollaborationMember | |
| CY2021Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
rcus:CollaborationMember | |
| CY2020Q1 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
rcus:CollaborationMember | |
| CY2021Q1 | us-gaap |
Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
|
5235000 | |
| CY2021Q1 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
1029000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
57986000 | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
12243000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
12781000 | |
| CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
9461000 | |
| CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1750000 | |
| CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1750000 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
66387000 | |
| CY2021Q1 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
4924000 | |
| CY2020Q4 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
943000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
23142000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
15821000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7008000 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
82208000 | |
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
7000 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
44000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
664790000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
502304000 | |
| CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
935119000 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
772292000 | |
| CY2021Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
7711000 | |
| CY2020Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
0 | |
| CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
9461000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
30150000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-28400000 | |
| CY2021Q1 | rcus |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
23023000 | |
| CY2020Q4 | rcus |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
18307000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9543000 | |
| CY2021Q1 | rcus |
Deferred Revenue Related Parties Classified Current
DeferredRevenueRelatedPartiesClassifiedCurrent
|
67571000 | |
| CY2020Q4 | rcus |
Deferred Revenue Related Parties Classified Current
DeferredRevenueRelatedPartiesClassifiedCurrent
|
67571000 | |
| CY2021Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
74571000 | |
| CY2020Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
74571000 | |
| CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3566000 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
121669000 | |
| CY2021Q1 | rcus |
Deferred Revenue Related Parties Noncurrent
DeferredRevenueRelatedPartiesNoncurrent
|
110097000 | |
| CY2020Q4 | rcus |
Deferred Revenue Related Parties Noncurrent
DeferredRevenueRelatedPartiesNoncurrent
|
117808000 | |
| CY2021Q1 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
113369000 | |
| CY2020Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
122830000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
14706000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
15243000 | |
| CY2021Q1 | rcus |
Related Parties Contract Liabilities Noncurrent
RelatedPartiesContractLiabilitiesNoncurrent
|
9703000 | |
| CY2020Q4 | rcus |
Related Parties Contract Liabilities Noncurrent
RelatedPartiesContractLiabilitiesNoncurrent
|
9703000 | |
| CY2020Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
10246000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
269988000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
400000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
400000000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
70965513 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
70965513 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
65114685 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
65114685 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
6000 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1065562000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
830438000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-400777000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-328184000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
49150000 | |
| CY2021Q1 | rcus |
Proceeds From Sale Of Short Term And Long Term Investments
ProceedsFromSaleOfShortTermAndLongTermInvestments
|
7500000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
3641000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
209000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-72593000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-46000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
224000 | |
| CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-72639000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-27529000 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-1.08 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.63 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
44282607 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
163842000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
643000 | |
| CY2020Q1 | rcus |
Stock Issued During Period Value Vesting Of Early Exercised Stock Option
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption
|
220000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3462000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
224000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27753000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
502304000 | |
| CY2021Q1 | rcus |
Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock
|
1885000 | |
| CY2021Q1 | rcus |
Stock Issued During Period Value Vesting Of Early Exercised Stock Option
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption
|
183000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
12761000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-46000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-72593000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
664790000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-72593000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-27753000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
12761000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3462000 | |
| CY2021Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
800000 | |
| CY2020Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
842000 | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
538000 | |
| CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
144000 | |
| CY2021Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-506000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
248000 | |
| CY2021Q1 | rcus |
Receivable From Related Party
ReceivableFromRelatedParty
|
3981000 | |
| CY2020Q1 | rcus |
Receivable From Related Party
ReceivableFromRelatedParty
|
0 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
|
4186000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
|
212000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4568000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3704000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-63000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
91000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
7722000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2342000 | |
| CY2021Q1 | rcus |
Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
|
4716000 | |
| CY2020Q1 | rcus |
Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
|
2226000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-2007000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-1578000 | |
| CY2021Q1 | rcus |
Deferred Revenue From Related Party
DeferredRevenueFromRelatedParty
|
7711000 | |
| CY2020Q1 | rcus |
Deferred Revenue From Related Party
DeferredRevenueFromRelatedParty
|
0 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-9461000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1750000 | |
| CY2020Q1 | rcus |
Repurchase Of Unvested Shares Of Stock
RepurchaseOfUnvestedSharesOfStock
|
33000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
222120000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
610000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
218630000 | |
| CY2021Q1 | rcus |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-605000 | |
| CY2020Q1 | rcus |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-273000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
9389000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
173618000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
58140000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
392248000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
62826000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
40056000 | |
| CY2021Q1 | rcus |
Proceeds From Issuance Of Common Stock To Related Party
ProceedsFromIssuanceOfCommonStockToRelatedParty
|
220235000 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
1885000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
643000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-2000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-66316000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-31277000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
192398000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
8885000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
|
251365000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
67529000 | |
| CY2021Q1 | rcus |
Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
|
927000 | |
| CY2020Q1 | rcus |
Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
|
519000 | |
| CY2021Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2784000 | |
| CY2020Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
76000 | |
| CY2021Q1 | rcus |
Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
|
183000 | |
| CY2020Q1 | rcus |
Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
|
220000 | |
| CY2021Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Note </span><span style="color:#000000;">1. </span>Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arcus Biosciences, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. The Company’s initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. Since its inception in 2015, the Company has built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which the Company is developing in combination with its in-licensed monoclonal antibodies through rationally designed, indication-specific clinical trial designs. The Company currently has five investigational products in clinical development: domvanalimab (formerly referred to as AB154), etrumadenant (formerly referred to as AB928), AB680, zimberelimab (formerly referred to as AB122), and AB308.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the Company had cash and investments of $884.9 million, which are cash, cash equivalents, and investments in marketable securities, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the date of filing of this report.</p> | |
| CY2021Q1 | rcus |
Number Of Investigational Product
NumberOfInvestigationalProduct
|
5 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates. </p> | |
| CY2021Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q4 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q4 | us-gaap |
Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020Q4 | us-gaap |
Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | |
| CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
390260000 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
67326000 | |
| CY2021Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1988000 | |
| CY2020Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
203000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
392248000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
67529000 | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments. </p> | |
| CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | |
| CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | |
| CY2021Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | |
| CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
|
0 | |
| CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
|
0 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
6440000 | |
| CY2021Q1 | rcus |
Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
|
884912000 | |
| CY2020Q4 | rcus |
Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
|
735086000 | |
| CY2021Q1 | us-gaap |
Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
|
0 | |
| CY2020 | us-gaap |
Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
|
0 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7536000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
884914000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
56000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
58000 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
390260000 | |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
173415000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
436666000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
555231000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
57986000 | |
| CY2021Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
884912000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
735042000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
57000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
13000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
735086000 | |
| CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7128000 | |
| CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8632000 | |
| CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
67000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
295000 | |
| CY2021Q1 | rcus |
Other Accrued Liabilities
OtherAccruedLiabilities
|
341000 | |
| CY2020Q4 | rcus |
Other Accrued Liabilities
OtherAccruedLiabilities
|
616000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9543000 | |
| CY2021Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
9461000 | |
| CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1750000 | |
| CY2021Q1 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
9461000 | |
| CY2020Q1 | us-gaap |
Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
|
1750000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-72593000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27753000 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
68476799 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
45953213 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
1394638 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
1670606 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
67082161 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
44282607 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.08 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.63 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
14706123 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8359101 |
